19 November 2026 | Thursday | News
Celosia Therapeutics, an Australian biotech company developing advanced gene therapies for neurodegenerative diseases, is pleased to announce that it has been awarded $2 million by the New South Wales Government’s Emerging Technology Commercialisation Fund (ETCF). The funding will support the development of a next-generation gene therapy candidate for motor neurone disease (MND).
Celosia was one of six organisations chosen from more than 250 applicants, and the only recipient of the maximum grant amount of $2 million.
Dr Kathryn Sunn, Chief Executive Officer at Celosia Therapeutics, said: “We are delighted and honoured to receive this support from the NSW Government to advance a next-generation gene therapy candidate for MND.
This funding will help us expand our MND pipeline, supporting candidate development, manufacturing work and preclinical studies alongside our lead program, CTx1000, which is currently being studied in patients with sporadic amyotrophic lateral sclerosis (ALS), the most common form of MND. It is an investment in Australian research and the capabilities needed to translate scientific discoveries into potential new treatments for people living with devastating neurodegenerative diseases.”
Minister for Innovation, Science and Technology Anoulack Chanthivong said: “NSW is home to some of the brightest researchers, entrepreneurs and innovators in the world, but great ideas only create jobs and economic opportunities when they make it out of the lab and into the marketplace.
The Emerging Technology Commercialisation Fund is about helping small innovative NSW businesses take that leap.
By backing homegrown innovation today, we’re helping build the industries, jobs and economic growth of tomorrow.”
Most Read
Bio Jobs
News